New malaria vaccine 100% effective

 YIDA REFUGEE CAMP, SOUTH SUDAN - JULY 5: A child gets a vaccination at the CARE medical clinic at Yida refugee camp along the border with North Sudan July 5, 2012 in Yida, South Sudan. Yida refugee camp grows each day and now has swollen to 64,317, as the refugees continue to flee from South Kordofan in North Sudan. The numbers of refugees arriving from North Sudan vary from 500 to 1,000 a day. Many new arrivals have walked from 3 to 5 days to reach the camp, most without food. The rainy season has increased the numbers suffering from diarrhea, severe malnutrition and malaria with sanitation issues causing the increased illness. Field hospitals say that 95% of all patients are under the age of five. (Photo by Paula Bronstein/Getty Images)

Paula Bronstein/Getty Images

“…This is a pivotal success,” said Stefan Kappe, a malaria researcher at the Seattle Biomedical Research Institute in Washington.

Hope for a cure to malaria is, at long-last, in large supply.

Sanaria, a company in Rockville, Maryland, has developed a malaria vaccine that has become the first in providing 100% protection against the deadly disease. The vaccine, which is called PfSPZ because its makeup is comprised of sporozoites (SPZ,) a stage of malarial parasite Plasmodium falciparum (Pf,) uses a weakened form of the malaria organism to instigate a response from the immune system.


In the safety trial’s first phase, the six subjects who were given five doses intravenously were completely protected from test bites of infectious mosquitos, whereas five of six unvaccinated control subjects developed malaria.

“The trial results constitute the most important advance in malaria vaccine development since the first demonstration of protection with radiation attenuated sporozoite immunization by mosquito bite in the 70s. This is a pivotal success,” said Stefan Kappe, a malaria researcher at the Seattle Biomedical Research Institute in Washington, to


The trial will need to be carried over to a wider array of subjects to see if the vaccine will work on the varied strains of the disease and if it continues to provide the same protection for different genders and ages.

Health – NY Daily News

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>